Your browser doesn't support javascript.
loading
HIV-Associated Nephropathy in 2022.
Rivera, Frederick Berro; Ansay, Marie Francesca Mapua; Golbin, Jem Marie; Alfonso, Pia Gabrielle I; Mangubat, Gerard Francis E; Menghrajani, Rajiv Hans Solita; Placino, Siena; Taliño, Marianne Katharina Vicera; De Luna, Deogracias Villa; Cabrera, Nicolo; Trinidad, Carlo Nemesio; Kazory, Amir.
Affiliation
  • Rivera FB; Department of Medicine, Lincoln Medical Center, New York, New York, USA.
  • Ansay MFM; Ateneo de Manila School of Medicine and Public Health, Pasig, Philippines.
  • Golbin JM; University of the Philippines System, Manila, Philippines.
  • Alfonso PGI; University of the Philippines System, Manila, Philippines.
  • Mangubat GFE; Department of Medicine, Southern Philippines Medical Center, Davao City, Philippines.
  • Menghrajani RHS; St. Luke's Medical Center College of Medicine - William H. Quasha Memorial, Quezon City, Philippines.
  • Placino S; St. Luke's Medical Center College of Medicine - William H. Quasha Memorial, Quezon City, Philippines.
  • Taliño MKV; Ateneo de Manila School of Medicine and Public Health, Pasig, Philippines.
  • De Luna DV; Department of Internal Medicine, Danbury Hospital, Danbury, Connecticut, USA.
  • Cabrera N; Division of Infectious Diseases, George Washington University, Washington, District of Columbia, USA.
  • Trinidad CN; Section of Nephrology, University of the Philippines-Philippine General Hospital, Manila, Philippines.
  • Kazory A; Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, Florida, USA.
Glomerular Dis ; 3(1): 1-11, 2023.
Article in En | MEDLINE | ID: mdl-36816427
ABSTRACT

Background:

HIV-associated nephropathy (HIVAN) is a renal parenchymal disease that occurs exclusively in people living with HIV. It is a serious kidney condition that may possibly lead to end-stage kidney disease, particularly in the HIV-1 seropositive patients.

Summary:

The African-American population has increased susceptibility to this comorbidity due to a strong association found in the APOL1 gene, specifically two missense mutations in the G1 allele and a frameshift deletion in the G2 allele, although a "second-hit" event is postulated to have a role in the development of HIVAN. HIVAN presents with proteinuria, particularly in the nephrotic range, as with other kidney diseases. The diagnosis requires biopsy and typically presents with collapsing subtype focal segmental glomerulosclerosis and microcyst formation in the tubulointerstitial region. Gaps still exist in the definitive treatment of HIVAN - concurrent use of antiretroviral therapy and adjunctive management with like renal-angiotensin-aldosterone system inhibitors, steroids, or renal replacement therapy showed benefits. Key Message This study reviews the current understanding of HIVAN including its epidemiology, mechanism of disease, related genetic factors, clinical profile, and pathophysiologic effects of management options for patients.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: Glomerular Dis Year: 2023 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: Glomerular Dis Year: 2023 Document type: Article Affiliation country: United States
...